HALIFAX, NS / ACCESSWIRE / / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing ...

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The ...

WUXI BIO (02269.HK) announced that it had inked a research service collaboration agreement with Candid Therapeutics. Under ...

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trial ...

Monoclonal Antibodies IndustryThe global monoclonal antibodies (mAbs) industry, valued at USD 186 billion in 2021, is ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its ...

Under the terms of the license agreement, Immunome will be responsible for the research, development, manufacturing and ...

I-Mab said it has paused the development of uliledlimab to focus on a Phase I trial of its lead candidate givastomig.

Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.

Shares of Fusion Antibodies plc (LON:FAB – Get Free Report) reached a new 52-week high on Friday . The company traded as high as GBX 10.25 ($0.13) and last traded at GBX 10.23 ($0.13), with a volume ...